Zacks Investment Management Gilead Sciences, Inc. Transaction History

Zacks Investment Management

$9.31 Billion
Q1 2024

A detailed history of Zacks Investment Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 328,821 shares of GILD stock, worth $22.5 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

328,821

Previous 717,589 54.18%

Holding current value

$22.5 Million

Previous $58.1 Million 58.57%

% of portfolio

0.26%

Previous 0.72%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $27.8 Million - $33.9 Million	-388,768 Reduced 54.18%	328,821 $24.1 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $2.51 Million - $2.84 Million	-34,211 Reduced 4.55%	717,589 $58.1 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $169,544 - $184,976	2,293 Added 0.31%	751,800 $56.3 Million
Q2 2023 Aug 15, 2023	BUY	$76.01 - $86.7 $3.95 Million - $4.51 Million	51,973 Added 7.45%	749,507 $57.8 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $3.5 Million - $3.99 Million	-46,040 Reduced 6.19%	697,534 $53.8 Million

Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1.66 Million - $1.89 Million	21,503 Added 2.98%	743,574 $61.7 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $8.47 Million - $12.2 Million	135,927 Added 23.19%	722,071 $62 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.02 Million - $1.17 Million	17,202 Added 3.02%	586,144 $36.2 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $1.82 Million - $2.05 Million	31,470 Added 5.86%	568,942 $35.2 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $1.78 Million - $2.23 Million	30,678 Added 6.05%	537,472 $32 Million
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $499,770 - $567,248	7,703 Added 1.54%	506,794 $36.8 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $891,341 - $961,659	13,168 Added 2.71%	499,091 $34.9 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $1.49 Million - $1.63 Million	23,480 Added 5.08%	485,923 $33.5 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $1.14 Million - $1.3 Million	-18,938 Reduced 3.93%	462,443 $29.9 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $6.06 Million - $6.91 Million	-106,991 Reduced 18.18%	481,381 $28 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $4.7 Million - $5.91 Million	75,632 Added 14.75%	588,372 $37.2 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $1.88 Million - $2.18 Million	-25,999 Reduced 4.83%	512,740 $39.5 Million
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $1.78 Million - $2.28 Million	28,364 Added 5.56%	538,739 $40.3 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $1.47 Million - $1.62 Million	-23,915 Reduced 4.48%	510,375 $33.2 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $755,245 - $833,658	12,082 Added 2.31%	534,290 $33.9 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $393,926 - $441,742	6,367 Added 1.23%	522,208 $35.3 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $1.31 Million - $1.47 Million	20,974 Added 4.24%	515,841 $33.5 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $2.01 Million - $2.63 Million	-33,231 Reduced 6.29%	494,867 $31 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $1.86 Million - $2.06 Million	-26,158 Reduced 4.72%	528,098 $40.8 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $273,209 - $318,688	4,211 Added 0.77%	554,256 $39.3 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $412,492 - $502,874	5,663 Added 1.04%	550,045 $41.5 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $4.02 Million - $4.72 Million	-56,503 Reduced 9.4%	544,382 $39 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $43.3 Million - $51.4 Million	600,885	600,885 $48.7 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.

Account

Zacks Investment Management Gilead Sciences, Inc. Transaction History